About

Levicept is a UK-based biotechnology company developing a novel, efficacious biological therapy, LEVI-04, for the treatment of chronic pain. 

With more than 1 billion people worldwide living with some type of chronic pain, there is a critical unmet need for effective, well-tolerated analgesics. 

LEVI-04 has successfully completed a phase II clinical trial in patients with osteoarthritis of the knee. LEVI-04 modulates the neurotrophin pathway via neurotrophin-3. Clinically proven to provide effective analgesia in a range of indications, it is designed to minimise use-limiting side effects.

Watch BiotechTV interview HERE 

---